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ABSTRACT 
 
Background and aims: New options are needed for the management and prevention of 
colorectal cancer liver metastases. Interleukin-12 (IL-12) is an immunostimulatory 
cytokine with proven antitumor effect in animal models. Despite evidences indicating 
its biological effect in humans, neither the recombinant protein nor gene therapy vectors 
expressing IL-12 have shown a relevant benefit in cancer patients. The difficulties in 
obtaining a suitable expression pattern and the immunosuppressive milieu in the tumors 
contribute to this poor performance. We propose a new approach to overcome these 
limitations. 
Methods: A High-Capacity (“gutless”) Adenoviral vector carrying a liver-specific, 
Mifepristone (Mif)-inducible system for the expression of IL-12 (HC-Ad/RUmIL-12) 
was used in combination with chemotherapy. Tumors were established in the liver of 
C57BL/6 mice by inoculation of MC38 colon cancer cells.  
Results: Intrahepatic injection of HC-Ad/RUmIL-12 and tailored induction regimes 
allowed the maintenance of safe and efficient levels of IL-12 in vivo. Individualized, 
step-wise increase in the dose of Mifepristone (125-4000 μg/kg) was needed to 
compensate the progressive but transient downregulation of the inducible system. 
Repeated cycles of Mif induction (every 24 hours for 10 days) were needed for optimal 
tumor eradication. However, complete protection against tumor re-challenge was 
observed in less than 25% of the animals. The administration of oxaliplatin (5 mg/kg 
intraperitoneally) three days before starting the induction regime achieved efficient 
elimination of liver metastases with a single cycle of IL-12 induction, and improved 
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protection against tumor re-challenge. This was associated with a shift in the tumor 
microenvironment towards a more pro-immunogenic phenotype, with an increase in the 
CD8+/T regulatory cell ratio and a reduction in myeloid-derived suppressor cells. These 
effects were not observed with 5-Fluorouracil, irinotecan or gemcitabine. 
Conclusions: Long-term controlled expression of IL-12 using a HC-Ad vector in 
combination with oxaliplatin is effective and clinically applicable against hepatic colon 
cancer metastases. 
 
SUMMARY 
What is already know about this subject: 
• IL-12 is an immunostimulatory cytokine with antitumor effects in animal 
models of colorectal cancer. 
• Methods to control the location, intensity and duration of IL-12 production are 
needed to increase the safety and efficacy of genetic immunotherapy. 
• Tissue-specific, drug-inducible expression systems can be used to modulate the 
expression of transgenes in specific organs, but the biological effects of IL-12 
can interfere with their functions. 
• High-Capacity (“gutless”) adenoviral vectors are efficient in long-term gene 
transfer of the liver.  
What are the new findings: 
• Using the HC-Ad/RUmIL-12 vector, individualized step-wise increases in the 
dose of inducer allowed the maintenance of therapeutic levels of IL-12 for more 
than 10 days, in cycles that can be repeated over a period of several months in 
mice. 
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• Oxaliplatin cooperates with IL-12 in the stimulation of an efficient immune 
response against cancer cells, with complete eradication of pre-established 
colorectal cancer liver metastases and prevention of experimental relapses in a 
syngeneic model. 
• The mechanism of cooperation involves a reduction in the immunosuppressive 
microenvironment of tumors, with an increase in the ratio of CD8+/T regulatory 
cells and CD8+/myeloid-derived suppressor cells. 
• Cooperation with IL-12 is not observed with other chemotherapeutic drugs such 
as 5-Flurouracil, irinotecan and gemcitabine. 
Potential impact on clinical practice in the future: 
The protocol described here is compatible with conventional oxaliplatin-based 
chemotherapeutic regimes, and it can be applied in conjunction with surgical or 
ablative treatments to avoid recurrence of colorectal cancer liver metastases. 
 
 
INTRODUCTION 
 
Metastatic liver cancer is a life-threatening condition frequently observed in colorectal 
cancer patients. Hepatic lesions are found in 10 to 25% of cases at the time of diagnosis, 
and 30% of them have no evidence of dissemination in any other organ. In addition, 
recurrence after surgical removal of the colorectal tumor occurs mainly in the liver, with 
a 20-25% rate of metachronous liver metastases 1. Overall, more than 50% of colorectal 
cancer patients will suffer liver involvement during the course of their disease 2. 
Surgical resection is potentially curative only in the most favorable cases, with a general 
recurrence rate of 60-70%. Regional treatments achieve local control, but a significant 
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increase in long-term survival is not guaranteed. Standard chemotherapy combinations 
consisting on 5-flourouracil and leucovorin plus oxaliplatin or irinotecan (FOLFOX and 
FOLFIRI) achieve survival rates close to 10% in advanced colorectal cancer 3. The 
addition of biological agents such as cetuximab can increase the response rate 4 and 
allows resection of liver metastases that were not candidates for surgery before 
treatment 5. However, recurrence rate exceeds 70% and it is clear that new therapeutic 
options are needed to improve the clinical management of hepatic metastases from 
colon cancer. Diverse strategies aimed to stimulate the immune responses against cancer 
cells offer the opportunity to block progression of disseminated tumor deposits and 
prevent relapses 6. However, unraveling this potential is still a challenge in the clinical 
setting. Tumors avoid the attack of the immune system by promoting the development 
and accumulation of leukocytes with an immunosuppressive phenotype. The importance 
of regulatory T cells (Treg) and Myeloid-Derived Suppressor Cells (MDSC) in this 
process has been recently demonstrated (reviewed in 7, 8). The effect of cancer 
treatments on these cell populations is still poorly understood, but it can greatly 
influence their efficacy. Exploring the opportunities of cooperation with standard 
treatments is especially important, in light of the recent realization that certain cytotoxic 
drugs can favor the immune response against tumors 9. These include some of the most 
active agents against colorectal cancer, such as oxaliplatin (OXP), 5-fluorouracil (5-FU) 
and gemcitabine 10-14.  
 The cytokine interleukin-12 (IL-12) can serve as a link between the innate and 
adaptive immune responses because it can activate the proliferation of T lymphocytes 
and Natural Killer (NK) cells, the secretion of other mediators such as interferon-γ 
(IFN-γ), and the cytotoxic activity of these effector cells 15. The capacity of IL-12 to 
increase the number and activity of tumor-specific lymphocytes has been verified in 
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humans 16, and certain antitumor effect has been observed 17. However, clinical 
responses tend to be poor, and intensification of the treatment is difficult due to the 
toxicity associated with systemic exposure to IL-12. The use of gene therapy vectors 
encoding the p35 and p40 IL-12 subunits to obtain expression of the cytokine in specific 
locations is an attractive alternative 18-20. However, the clinical experience indicates that 
refinement of these vectors is needed. Intratumoral administration of a replication-
deficient adenovirus carrying the IL-12 gene was well tolerated in patients with hepatic 
metastases 21. Biological effect was demonstrated, but antitumor responses were very 
modest. The poor performance of the vector in terms of intensity and duration of 
expression was recognized as a key limitation in this approach. Additional obstacles are 
the high heterogeneity in the infectivity of tumor nodules among different patients, and 
the rapid appearance of neutralizing antibodies against adenovirus, which makes 
subsequent administrations ineffective 22. To circumvent these problems, High-Capacity 
adenoviral vectors (HC-Ad) have been designed. The lack of viral genes reduces their 
toxicity and avoids the elimination of transduced hepatocytes by the immune system 23-
26
. The incorporation of a liver-specific, drug-inducible expression system in the GL-
Ad/RUmIL12 vector (called here HC-Ad/RUmIL-12) allowed intense, controlled and 
long-term expression of the transgene upon intravenous administration of the vector 27. 
The possibility of controlling the intensity of IL-12 expression by adjusting the dose of 
inducer makes this approach safer and more clinically applicable. However, the function 
of drug-inducible expression systems is influenced by the immunostimulatory properties 
of IL-12 acting at the transcriptional level 28. This causes a progressive but reversible 
inhibition of transgene expression that might limit the therapeutic effect of this 
approach, especially in the case of pre-established liver metastases 29, 30. We 
hypothesized that optimization of the induction regime and combination with 
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chemotherapy would render a more efficient and clinically relevant protocol. We 
describe here an individualized induction scheme that prevents toxicity, compensates 
the downregulation of the system, and allows several rounds of sustained IL-12 
expression. More importantly, we found that the combination with systemic OXP 
favored the immune response against tumors, alleviated the need for long-term IL-12 
expression, and increased the protection from an experimental tumor re-challenge. This 
treatment achieved complete eradication of hepatic lesions and long-term disease-free 
survival of animals in a syngeneic model 29.  
 
 
 
 
 
MATERIALS AND METHODS 
 
Cell lines. 
The MC38Luc1 cell line has been previously described 29, 31. They were maintained in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), 100 μg/ml streptomycin and 100 μg/ml penicillin (all from of 
Gibco, Invitrogen), 2 mM glutamine (Cambrex) and 400 μg/ml G418 (geneticin, Gibco, 
Invitrogen).  
 
Mice and tumor models. 
Five to 8 weeks old C57BL/6 and athymic (nu/nu) female mice were purchased from 
Harlan and Charles river, respectively (Barcelona, Spain). Hepatic tumors were 
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established by direct implantation of 5x105 MC38Luc1 cells, as previously described 29. 
For subcutaneous tumor formation (rechallenge experiments), a total of 106 cells were 
injected in the right hind flank. Tumor size was monitored at indicated time points by 
measuring two perpendicular tumor diameters using a precision caliper. Tumor volume 
was calculated using the following formula: V= length x width2 x 0.5. Survival was 
checked daily and mice were euthanized if general status was deteriorated or 
subcutaneous tumors exceeded 20 mm in diameter. All in vivo experiments were 
performed in accordance with the local animal commission. 
 
Bioluminescence imaging. 
Anesthetized animals received the substrate D-luciferin (Promega) by intraperitoneal 
injection at 150 mg/kg. Ten minutes later, light acquisition was performed in an IVIS 
CCD camera system (Xenogen) and analyzed with the Living Image 2.20 software 
package (Xenogen). Typically, a circular region of interest measuring 3 cm in diameter 
was defined in the abdomen of mice, and quantification of light emission was 
performed in photons/second.  
 
Vector and treatment procedures. 
The High-Capacity (gutless) adenoviral vector HC-Ad/RUmIL-12 (also named GL-
Ad/RUmIL12) has been previously described 27. In this vector, all viral genes have been 
deleted and substituted by human non-coding DNA (“stuffer”), plus a transgene region 
containing a Mif-inducible system for the expression of p35 and p40 subunits of murine 
IL-12. The transactivator of this system is expressed under the control of a liver-specific 
promoter (transthyretin). Both IL-12 subunits are co-expressed due to an internal 
ribosomal entry site (IRES). Amplification of the vector was carried out as previously 
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described 32. The virus was administered by direct intrahepatic injection surrounding the 
tumors following laparotomy 30. Typically, 2.5x108 infectious units (i.u.) of virus were 
mixed in a total volume of 50 μl saline solution before injection. Activation of the 
inducible system was carried out by intraperitoneal injection of Mif (RU486, Sigma) 
dissolved in sesame oil (Sigma). Inductions started 2 weeks after implantation of cells. 
Administration of chemotherapy drugs was carried out by intraperitoneal injection. 
OXP (Eloxatin®) was from Sanofi-aventis; 5-FU was from Ferrer Farma; irinotecan 
was from Hospira; gemcitabine (Gemzar®) was from Lilly. Animals treated with 5-FU 
received 50 mg/kg folinic acid (from GES) 1 hour before 5-FU, and another dose 
together with 5-FU.  
 
Determination of IL-12, IFN-γ and HMGB1.  
Serum concentration of murine IL-12 and IFN-γ were determined by OptE1A mouse 
IL-12 (p70) and mouse IFN-γ ELISA kits (BD Bioscience PharMingen, San Diego, 
CA). HMGB1 in serum or supernatant of cells was quantified by ELISA kit from IBL 
International GmbH (Hamburg, Germany).  
 
Flow cytometry 
Spleens, healthy livers and livers with tumors were harvested and treated with 400 
U/mL collagenase D and 50 μg/mL DNase I (Roche Diagnostics). After mechanical 
tissue dissociation, cells were passed through a 70-μm nylon mesh filter (BD Falcon, 
BD Bioscience, San Jose, CA, USA) and washed. To enrich liver cell suspension in 
leukocytes, hepatocytes were removed with Percoll gradients. The single cell 
suspension obtained was pre-treated with anti-CD16/32 (clone 2.4G2; BD Biosciences-
Pharmingen) to reduce non-specific binding to Fc receptors. Afterwards, cells were 
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stained with the following fluorochrome-conjugated antibodies: CD8 (53-6.7), CD4 
(clone RM4-5), CD25 (PC61), CD11b (M1/70), Ly6C (AL-21), F4/80 (BM8) and Ly6G 
(1A8) from BD Pharmingen. Intracellular staining for FoxP3 was performed using 
mouse Regulatory T cell staining kit BD Biosciences following manufacturer´s 
instructions. Cells were acquired on either a FACSCalibur or a FACSCanto flow 
cytometer (BD Biosciences). Flow cytometry data were analyzed using FlowJo software 
(Tree Star). CD8/Treg or CD8/MDSC ratios were calculated as CD8 T cell count 
divided by either Treg cell or MDSC count. 
 
Statistical analysis. 
Two-tailed unpaired t-test was used to compare two groups of values when n>10. For 
smaller groups, Mann-Whitney non-parametric test was used. Comparisons of more 
than two groups were performed using ANOVA test with Bonferroni correction. 
Survival curves were compared by logrank test (GraphPad Prism software). 
 
RESULTS 
 
Individualized and progressive adjustment of Mif compensates transduction 
variability and downregulation of the inducible system. 
Therapeutic use of IL-12 requires efficient methods to control the plasmatic levels of 
this potent immunostimulatory cytokine in order to avoid toxicity. We had previously 
determined in our MC38 syngeneic tumor model that seric IL-12 below 20 ng/ml has no 
antitumor effect, and levels above 700 ng/ml are associated with toxicity 27. The two 
main obstacles for keeping this therapeutic range are the variability in transduction 
among individuals and the progressive silencing of the drug-inducible system mediated 
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by the immune system 28. We have focused on the favorable dose-response effect of the 
Mifepristone (Mif)-inducible system (figure 1A) to design a new induction protocol. 
Once the liver has been transduced with the vector (typically 2.5x108 iu), a sub-optimal 
amount of Mif (125 µg/kg) is administered the first two days in order to prevent 
toxicity. The concentration of IL-12 is measured in serum 10 hours after the first 
induction, and based on this information, an step-wise increase in Mif is scheduled 
according to table 1. In figure 1B we represent the kinetics of IL-12 production obtained 
with the adjusted protocol. In contrast with a fixed amount of inducer (constant 
protocol), doubling the dose of Mif every 3 days contributes to the stabilization of IL-12 
levels for at least 10 days. Since downregulation of the system is due to a reversible 
inhibition of the transthyretin promoter 28, the induction protocols can be repeated after 
a resting period of at least 2 weeks in order to obtain several cycles of IL-12 expression 
(figure 2B). We have verified that the system is functional for more than 5 months, with 
a slow decrease in the intensity of expression in each cycle due to the non-integrative 
nature of adenoviral vectors.  
 
Combination with OXP increases the antitumor effect of IL-12 on hepatic colon 
cancer metastases. 
Once the induction protocol was established, we investigated if conventional OXP-
based chemotherapy could enhance the antitumor effect of sustained IL-12 expression. 
Tumors were obtained by direct inoculation of MC38Luc1 cells in the liver of 
syngeneic mice 29. Bioluminescence detection ensured engraftment of cancer cells and 
homogeneous tumor load in all experimental groups (not shown). The HC-Ad/RUmIL-
12 vector was injected intrahepatically in the proximity of tumors nodules, as recently 
described 30. One week later, daily inductions started following the adjusted protocol 
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described above. One subset of these animals received a single dose of OXP (5 mg/kg 
intraperitoneally) three days before the first Mif administration. Other mice were 
inoculated intrahepatically with saline solution instead of vector, with no additional 
treatment (control group), or received a single dose of OXP. A schematic representation 
of the experiments is provided in figure 2A. Two weeks after completing one cycle of 
inductions (day 35 after cell implantation), most animals from the control or OXP-only 
groups were dead as a consequence of tumor progression (see figure 2D). At this point, 
bioluminescence quantification predicted the presence of hepatic tumors in 
approximately half of the animals treated with intrahepatic IL-12 alone, whereas the 
addition of OXP achieved a stronger and more homogeneous inhibition of luciferase 
signal (figure 2B). To confirm this observation, all surviving animals underwent 
laparotomy 5 days later. In figure 2C we represent the volume of tumors determined by 
direct measurement at this stage, or after necropsy in animals with shorter survival. The 
result clearly demonstrates that the combination of IL-12 and OXP achieves the best 
therapeutic effect, both in terms of antitumor effect and long-term survival (figure 2D). 
Treatment with OXP alone caused a small, not statistically significant reduction in the 
final tumor volume, but no survival advantage was observed. The lack of efficacy of 
OXP in aggressive models based on MC38 cells has been described by other groups 33.  
 
OXP enhances the establishment of a protective immune response against a tumor 
rechallenge. 
Protection from tumor relapse or from the appearance of new liver metastases is crucial 
to improve the prognosis of colorectal cancer patients. Therefore, we studied the 
immunological protection provided by our treatments against a tumor rechallenge. 
Animals that remained free from their hepatic tumors for more than one month after 
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being treated with HC-Ad/RUmIL-12 (with or without OXP) received a new 
inoculation of MC38Luc1 cells in a distant location (subcutaneous). Monitorization of 
tumor growth revealed that, on average, mice from both treatment groups presented a 
delay in tumor progression compared with naïve animals (figure 3). Interestingly, the 
inhibition was more intense if the treatment regime had included OXP, and the 
proportion of animals that were completely protected from the appearance of new 
tumors increased from 23 to 55%.  
 
OXP counteracts the immunosuppressive microenvironment of tumors.  
We investigated the mechanisms involved in the cooperation between IL-12 and OXP. 
First, we verified that IL-12 does not increase the cytotoxic activity of OXP in 
MC38Luc1 cells in vitro (supplementary figure 1). Although the influence of direct 
cytotoxicity cannot be completely ruled out in vivo, experiments performed in athymic 
(nu-/nu-) mice showed a dramatic loss of therapeutic effect (supplementary figure 2), 
demonstrating a critical role T cell-mediated immune responses. Exposure of 
calreticulin (CRT) on the cell surface and release of high-mobility group box 1 protein 
(HMGB1) have been proposed as key elements in the immunostimulatory properties of 
oxaliplatin 14. Whereas we did not detect a significant increase in the exposure of CRT 
upon treatment of MC38Luc1 cells with OXP (data not shown), the release of HMGB1 
was evident (supplementary figure 1A). However, the biological significance of this 
finding in our tumor model is uncertain, because tumor-bearing animals treated with 
HC-Ad/RUmIL-12 plus OXP did not show an increase in the serum concentration of 
HMGB1 compared with untreated mice (figure 4A). This is probably due to the fact that 
MC38Luc1 tumors spontaneously release increasing amounts of HMBG1 as they 
progress in the liver of the animals, in correlation with the situation observed in 
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advanced colorectal cancer patients 34. This is in contrast with other tumor models such 
as glioblastoma multiforme in which HMGB1 levels are low in untreated animals, but 
show an acute increase in response to suicide gene therapy 35. Next, we verified that 
OXP does not cause a significant increase in the production of IL-12 mediated by HC-
Ad/RUmIL-12 (data not shown). However, the amount of IFN-γ produced in response 
of IL-12 was higher in the group treated with OXP (figure 4B), suggesting a stronger 
activation of the immune system. This effect was observed 6 days after the initiation of 
IL-12 expression, and coincides with the peak of IFN-γ stimulation. Using MHC-
tetramer staining specific for an MC38 epitope we detected a moderate increase in the 
frequency of CD8+ T lymphocytes in peripheral blood in response to IL-12, but the 
addition of OXP did not increase significantly this population (data not shown).  
 Therefore, we studied the tumor microenvironment to evaluate if the combined 
treatment had an effect on the local immunosuppressive cell populations. A favourable 
balance between T-effector and T-suppressor cells has been associated with improved 
immune responses against tumors 36, 37. Tumor, liver and spleen from control and treated 
animals were collected 3 days after the initiation of IL-12 expression, and leukocyte 
populations were analyzed by flow cytometry. We did not observe changes in the NK 
cells in any of these tissues (data not shown). However, the ratio between CD8+ T 
lymphocytes and Tregs (CD25+FoxP3+ population) was significantly increased in the 
tumors of mice treated with IL-12 in combination with OXP, in comparison with IL-12 
alone. Interestingly, this effect was not observed neither in the surrounding liver, nor in 
the spleen of these animals (figure 5A, B). Similar results were obtained in samples 
obtained the 6th day of IL-12 induction (not shown). In addition, we found that the 
combined treatment caused a decrease in the monocytic Myeloid Derived Suppressor 
Cells (MDSC), defined as the CD11b+Ly6C+Ly6G- population 38. The ratio 
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CD8+/MDSC was slightly elevated in the tumors of mice treated with IL-12, but it was 
significantly enhanced if OXP was included in the therapeutic regime (figure 5A, C). In 
this case, the ratio was also increased in the spleen, but not in the liver. Since monocytic 
MDSC have the potential to differentiate into tumor-associated macrophages (TAM) 7, 
38
, we determined if the treatment induced changes in the expression of the macrophage 
differentiation marker F4/80. We found that the vast majority of myeloid-derived cells 
in our tumor model remained in an undifferentiated state, and no changes were observed 
with any of the treatment conditions (supplementary figure 3). Together, these data 
indicate that of OXP collaborates with IL-12 to reduce the immunosuppressive 
microenvironment of tumors. This effect is not shared by other agents frequently used 
against colorectal cancer. For instance, treatment with irinotecan alone or in 
combination with HC-Ad/RUmIL-12 did not increase the CD8/Treg and CD8/MDSC 
ratios (figure 6A and B). Interestingly, we found that 5-FU and gemcitabine caused an 
increase in the CD8/MDSC ratio, in accordance with recent reports 39, 40. However, this 
effect was reversed when the drugs were combined with IL-12. Although irinotecan and 
gemcitabine cooperated with IL-12 in the eradication hepatic lesions and increased the 
survival of animals (figure 6C), they did not improve the immunological protection 
against tumor rechallenge (figure 6D), suggesting that alternative mechanisms are 
taking place.  
 
Repeated cycles of IL-12 plus OXP are efficient in the long-term management of 
colorectal liver metastases. 
Potential clinical application of immunochemotherapy will surely require repeated 
cycles of treatment not only to control the initial lesions, but also to prevent or 
eventually cope with relapses and the appearance of new metastases. In order to mimic 
 16
this situation, we initiated a series of experiments in which mice bearing hepatic tumors 
were treated with two cycles of IL-12 induction after vector administration. Then, they 
were subjected to a subcutaneous tumor rechallenge and finally a third cycle of 
induction was completed. In total, mice were evaluated for 5 months from the 
establishment of the initial hepatic tumors (see schematic representation in figure 7A). 
Three days before each one of these cycles, one group of animals received a single dose 
of OXP (5 mg/kg). Interestingly, we observed that two cycles of IL-12 induction 
separated by two weeks achieved a very efficient control of the hepatic tumors and 
extended survival of mice (figure 7B, left part of the graphic). In this setting, the 
cooperation of OXP was not apparent because most animals were cured. One month 
after the completion of the second cycle of induction, the subcutaneous tumor challenge 
was performed in mice that had rejected the hepatic lesions. Compared with the results 
obtained with a single cycle of induction, no increase in the immunological protection 
was observed with any of the treatments. Therefore, we had the opportunity to evaluate 
if a third cycle of induction was able to control the progression of the subcutaneous 
tumors, as if they were distant metastases. As shown in figure 7C, IL-12 alone was 
unable to inhibit the growth of the tumors that had escaped the initial immunological 
protection. In contrast, the combination of IL-12 and OXP obtained a response in 60% 
of them (figure 7C). Of note, these tumors had progressed for more than 3 weeks and 
some of them exceeded 1000 mm3 in volume before the third induction cycle started. As 
a result, the overall survival of animals, including deaths from the tumor rechallenge, 
was improved by the incorporation of OXP in the treatment (figure 7B, right part of the 
graphic).  
 
DISCUSSION 
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The development of a long-term expression vector based on adenovirus enables an 
efficient delivery of therapeutic genes in the liver 25. In the current approach, the target 
cells for transduction are the “normal” hepatocytes, not the cancer cells. This reduces 
the variability of infectivity and makes this approach more predictable in terms of gene 
transfer. The possibility of regulating the intensity of IL-12 expression by adjusting the 
dose of an inducer is important for the clinical application of immunogene therapy. It 
allows the use of relatively high doses of vector, to ensure that the liver of all patients is 
efficiently transduced. Then, careful monitorization of the individual response to the 
inducer will guide the intensification of the regime, a concept that is common to many 
oncologic treatments. Regarding Mif, there is abundant information about the safety of 
this drug at doses higher than those used here 41, 42, suggesting that there is still margin 
to increase the potency of the system. Predicting the duration of the treatment that 
would be needed in patients based on our pre-clinical results is too speculative. 
However, we provide evidence indicating that sustained expression of IL-12 is 
beneficial. One cycle of Mif induction is sub-optimal in our tumor model. Repetition of 
short cycles does not improve the efficacy (data not shown), meaning that it is important 
not only the number of cycles but also the duration of each one of them, i.e. the total 
period covered by therapeutic levels of IL-12. This requirement will probably depend 
on the severity of the disease. Although suppressive mechanisms used by tumors to 
evade the immune attack may be activated by IL-12 43, 44, the net balance on tumor 
control is still positive. Our data suggest that OXP may enhance the immune response 
against tumors by tipping the balance between effector and regulatory/suppressor cells 
in favor of effector cells, as it has been previously described for other chemotherapeutic 
drugs 37. Stimulation of T reg development by MDSCs has been described in some 
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tumor models 45, indicating that mutual influence of these suppressive populations is 
possible. It has been recently described that the inhibition of MDSC accumulation by 
sunitinib increases the antitumor effect of IL-12 46, supporting the relevance of this 
mechanism. The need of a complementary mechanism that initiates the damage to 
cancer cells may be particularly important in the protocol proposed here, since 
expression of IL-12 takes place in the liver parenchyma surrounding the tumor. 
Although we did not detect a consistent increase in the exposure of CRT in MC38 cells 
exposed to OXP, we cannot rule out the possibility that small amounts may contribute 
to immunogenicity of the cells, as recently described for other murine colon cancer cells 
14
. Our results point to a previously unrecognized mechanism taking place when OXP is 
used in combination with IL-12, but further studies are needed to gain a more detailed 
understanding of the immunostimulatory properties of OXP. The vector and the 
experimental conditions described here can be easily adapted to evaluate other 
immunochemotherapy combinations in search of new combined protocols. Careful 
testing of specific combinations is required, because the effect of drugs on the immune 
system can be different when used as monotherapy or in the context of IL-12 
stimulation, as suggested by the results obtained with 5-FU and gemcitabine. This 
phenomenon is currently under investigation. In summary, the finding that controlled 
expression of IL-12 in the liver can be a good complement for OXP-based 
chemotherapy regimes opens new possibilities for the management of advanced 
colorectal patients. 
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FIGURE LEGENDS. 
 
Table 1. Adaptation of the induction regime to the initial concentration of IL-12 in 
serum. Mif is administered daily by intraperitoneal injection. The first two days, a sub-
optimal dose of 125 μg/kg is given to all mice. The concentration of IL-12 is 
determined in the serum 10 h after the first Mif injection (first column on the left). 
Based on this information, the dose of Mif is established for days 3 to 5, and 
subsequently duplicated every 3 days. 
 
Figure 1. Progressive increase in the dose of Mif allows several cycles of sustained 
IL-12 expression in mice treated with the HC-Ad/RUmIL-12 vector. The vector was 
administered at 2.5x108 i.u./mouse in C57BL/6 mice by intrahepatic injection. A. Two 
weeks later, a single dose of Mif (125; 250; 1.000; 2.000 or 4.000 μg/kg) was 
administered intraperitoneally to different groups of animals (n=5). The concentration 
of IL-12 was measured in serum 10 h later. B. Mice received daily injections of 250 
μg/kg Mif for 10 consecutive days (constant protocol, white circles, n=10). A different 
set of animals received an adjusted protocol (black circles, n=8) consisting on 125 
μg/kg Mif days 1-2; 250 μg/kg days 3-5; 500 μg/kg days 5-7 and 1000 μg/kg days 9-11. 
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The concentration of IL-12 in serum was determined 10 h. after induction at the 
indicated days. More than 2 months after the last Mif administration, a second cycle of 
inductions was repeated in the same group of animals using an adjusted protocol that 
started at 250 μg/kg Mif. The grey area represents the range of IL-12 concentrations 
considered therapeutic in the MC38 tumor model. Error bars represent standard 
deviation. 
 
Figure 2. OXP increases the antitumor effect of IL-12 in a syngeneic model of 
colorectal cancer liver metastases. A. Schematic representation of the 
experiment. MC38Luc1 cells (5x105 cells/mouse) were inoculated in the liver of 
C57BL/6 mice at day 0. Control animals (Cont) were left untreated (intrahepatic 
injection of saline solution), or treated with OXP alone (5 mg/kg intraperitoneal, 
group OXP). Other groups received the HC-Ad/RUmIL-12 vector by intrahepatic 
injection surrounding the tumors at day 5. Daily inductions with Mif started at day 
12 using an adjusted protocol (group IL12). One subset of these animals received 
OXP (5mg/kg intraperitoneal) 3 days before the first Mif administration (group 
IL12+OXP). B. Bioluminescence quantification performed at day 35. At this 
point, most animals in the control and OXP groups were dead. C. Volume of 
hepatic tumors determined by direct measurement through laparotomy at day 40, 
or after necropsy at earlier time points in animals dead or sacrificed for ethical 
reasons. D Survival of animals. Statistical significance: **, p<0.001; *, p<0.05.  
 
Figure 3. Immunological protection against cancer cells in animals treated 
with IL-12 plus OXP. MC38Luc1 cells (106 cells/mouse) were inoculated 
subcutaneously in C57BL/6 mice that were cured from their hepatic tumors after 
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being treated with the HC-Ad/RUmIL-12 vector in the presence (group 
IL12+OXP) or absence (group IL12) of OXP. The same amount of cells was 
inoculated in naïve mice as a control. The average tumor volume for each group is 
represented. The percentage of mice that remained tumor-free for the entire 
observation period is indicated in parenthesis. Day 0 indicates the moment of 
inoculation of subcutaneous cells, which corresponds to at least one month after 
completion of the previous treatments. *, p<0.05. 
Figure 4. OXP enhances the immunostimulatory action of IL-12. Mice bearing 
intrahepatic MC38 tumors were treated with the HC-Ad/RUmIL-12 vector, and IL-12 
expression was induced with Mif following an adjusted protocol (IL12 group). A subset 
of animals received 5 mg/kg OXP intraperitoneally 3 days before the first induction 
(IL12+OXP group). Other groups were left untreated (cont), or treated with OXP only. 
Blood was collected 24 h after the administration of OXP (considered as day 1), and 10 
h. after the 1st, 3rd and 6th Mif inductions (days 3, 5 and 8, respectively). The 
concentration of HMGB1 (A) and IFN-γ (B) was determined by ELISA (n=10). *, 
p<0.05. 
 
Figure 5. OXP counteracts the immunosuppressive microenvironment of tumors. 
C57BL/6 mice bearing intrahepatic MC38 tumors were treated with the HC-
Ad/RUmIL-12 vector in the absence or presence of OXP, as indicated (n=10). IL-12 
expression was obtained using an adjusted induction protocol with Mif, and animals 
were sacrificed after the 3rd day of induction. Control groups include untreated animals 
(Cont) and mice treated with OXP alone (n=10). Leukocytes were isolated from liver, 
spleen and tumor samples. CD8+ T cells, Tregs (CD25+FoxP3+) and monocytic MDSC 
(CD11b+Ly6C+Ly6G-) were identified by flow cytometry. (A) Countour plots showing 
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the percentage of CD8 T cells (CD3+CD8+), Tregs (CD4+CD25+FoxP3+) and MDSC 
(CD11b+ly6C+Ly6G-) in representative mice treated with the HC-Ad/RUmIL-12 vector 
in the absence or presence of OXP (IL12 and IL12+OXP groups, respectively). 
Countour plots are gated on alive cells (CD8 T cells), CD4+ cells (Tregs) or CD11b+ 
cells (MDSC). (B and C) The fold increase in the ratio of CD8/Treg (B) and 
CD8/MDSC (C) are represented, considering the untreated group as a reference. 
 
Figure 6. Combination of IL-12 and other chemotherapeutic drugs. Mice bearing 
intrahepatic MC38 tumors were treated with the HC-Ad/RUmIL-12 vector, and IL-12 
expression was induced with Mif following an adjusted protocol (IL12 group). Subsets 
of animals received additional treatment with one of the following chemotherapeutic 
drugs: 25 mg/kg 5-FU plus 100 mg/kg leucovorin on 2 consecutive days, starting 3 days 
before the first Mif. induction (IL-12+5-FU); a single dose of 150 mg/kg irinotecan, two 
days before induction (IL12+Iri);. two doses of 60 mg/kg gemcitabine, 3 days and 24 h 
before induction (IL12+Gem). Other groups were left untreated (cont), or treated with 
the chemotherapeutic drugs only. Five animals from each group were sacrificed after 
the 3rd day of induction and tumors were processed for analysis of CD8+ T cells, Tregs 
(CD25+FoxP3+) and monocytic MDSC (CD11b+Ly6C+Ly6G-) by flow cytometry. The 
fold increase in the ratio of CD8/Treg (A) and CD8/MDSC (B) are represented, 
considering the untreated group as a reference. The remaining animals completed the 
full induction protocol and survival was monitored (C). Death of animals was due to 
tumor progression, except for 3 mice in the group of IL-12+Gem that died before the 
completion of the treatment due to toxicity and were excluded from the survival curve. 
Animals treated with the chemotherapy drugs without IL-12 had no survival benefit 
compared with the untreated group, and are not represented in the graphic. Cured 
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animals from the IL12, IL12+Iri and IL12+Gem groups received a subcutaneous re-
challenge with MC38Luc1 cells (106 cells/mouse). The same amount of cells was 
inoculated in naïve mice as a control. The average tumor volume for each group is 
represented (D). The percentage of mice that remained tumor-free for the entire 
observation period is indicated in parenthesis. *, p<0.05. 
 
Figure 7. Long-term management of colorectal cancer. Cooperation of OXP and 
IL-12 for the control of experimental relapses in distant locations. A. Schematic 
representation of experiments. C57BL/6 mice bearing hepatic tumors were treated with 
the HC-Ad/RUmIL-12 vector and received two cycles of Mif induction preceded or not 
with OXP (5 mg/kg, intraperitoneal). Animals cured from their hepatic tumors were 
subjected to a subcutaneous challenge with the same tumor cells (MC38Luc1), and 
received a third cycle of induction during the indicated days. B Overall survival of mice. 
The grey areas indicate the duration of each induction cycle. Most animals in the OXP 
and OXP+IL12 groups were cured from their hepatic tumors (not shown). The day of 
subcutaneous tumor rechallenge is marked with a vertical dotted line. “Control 
rechallenge” refers to naïve animals that were inoculated with tumor cells and received 
no treatment. Mice were sacrificed when tumor burden reached the ethical end point. 
Survival after rechallenge was significantly higher in all treated groups versus control 
(p<0.01). Survival of animals in the IL12+OXP group was significantly higher than in 
the IL-12 group (p<0.04). The progression of individual subcutaneous tumors in the 
rechallenge experiment is represented in panels C (group IL12) and D (group 
IL12+OXP). The duration of the induction protocol (Mif) and the day of administration 
of OXP are indicated. All naïve animals inoculated with tumor cells developed tumors 
that progressed in the absence of treatment (not shown).  
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Supplementary figure 1. Effects of IL-12 and chemotherapeutic agents on 
MC38Luc1 cells in vitro. A. MC38Luc1 cells were treated for 24 h with 200 μM OXP, 
and 24 h later the amount of HMBG1 released in the supernatant was analyzed by an 
ELISA kit, as indicated by the manufacturer. (B-E) Cells were treated for 24 h with 
increasing doses of OXP (B) Iri (C), Gem (D), or 5-FU (E), as indicated. Then, the 
chemotherapeutic agents were removed and cells were incubated for additional 48 h 
with 500 ng/ml IL-12. Viability was analyzed by crystal violet staining at the end of the 
experiment. The graphic represents the percentage of cells that survive to the treatment. 
 
Supplementary figure 2. Treatment of colorectal cancer liver metastases with IL-
12 plus OXP in athymic mice. MC38Luc1 cells (5x105 cells/mouse) were inoculated 
in the liver of athymic (nu-/nu-) mice at day 0. Control animals (Cont) were left 
untreated (intrahepatic injection of saline solution), or treated with OXP alone (5 mg/kg 
intraperitoneal, group OXP). Other groups received the HC-Ad/RUmIL-12 vector by 
intrahepatic injection surrounding the tumors at day 5. Daily inductions with Mif started 
at day 12 using an adjusted protocol (IL12 group). One subset of these animals received 
OXP (5mg/kg intraperitoneal) 3 days before the first Mif administration (group 
IL12+OXP). The survival of animals is represented. 
 
Supplementary figure 3. Analysis of TAM. C57BL/6 mice bearing intrahepatic MC38 
tumors were treated with the HC-Ad/RUmIL-12 vector in the absence or presence of 
OXP, or received an intrahepatic injection of saline as a control. IL-12 expression was 
obtained using an adjusted induction protocol with Mif, and animals were sacrificed 
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after the 3rd day of induction. Leukocytes were isolated from tumor samples, and TAM 
were quantified by flow cytometry using anti-F4/80 and CD11b antibodies.  
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